Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

NCT06179875 is registered in ClinicalTrials.gov with Viridian Therapeutics, Inc. as lead sponsor.

NCT NCT06179875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06179875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies
Lead sponsor
Viridian Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2024
Completion date
June 23, 2025
Enrollment
139 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease